Prurigo Nodularis is a skin condition causing itchy bumps. This study tests a new medicine, barzolvolimab (CDX-0159), to see if it helps those with this condition. You'll start with a 28-day screening to check if you qualify. If you're in, the treatment lasts 24 weeks, followed by a 16-week check-up period. During treatment, you'll receive barzolvolimab or a placebo (a fake treatment) through injections every 4 weeks. To join, you must be 18 or older, have prurigo nodularis diagnosed by a skin doctor with at least 20 nodules, and a severe itch score of 7 or more. You must also be willing to use a moisturizer daily and agree to use birth control if you can have children. People with certain other skin problems, infections, or who are pregnant can't join. Your study doctor will discuss more criteria with you.

• Participation lasts for about 10 months with multiple visits.
• You'll need to record symptoms daily in an electronic diary.
• Be ready to use moisturizer and follow birth control rules.